SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)-SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN

被引：45
|
作者：
Lagos, Rosanna [3 ]
DeVincenzo, John P. [2 ]
Munoz, Alma [3 ]
Hultquist, Micki [1 ]
Suzich, Joann [1 ]
Connor, Edward M. [1 ]
Losonsky, Genevieve A. [1 ]
机构：
[1] MedImmune LLC, Gaithersburg, MD 20878 USA
[2] Univ Tennessee, Childrens Fdn Res Ctr, Sch Med, Memphis, TN USA
[3] Ctr Para Vacunas En Desarrollo Chile, Santiago, Chile
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2009年 / 28卷 / 09期
关键词：
antibodies; bronchiolitis; monoclonal; antiviral agents clinical trial; motavizumab; pediatric; respiratory syncytial virus; viral load; DISEASE SEVERITY; PREVENTION; IMBALANCE; INFANTS; LOAD;
D O I：
10.1097/INF.0b013e3181a165e4
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.
引用
收藏
页码：835 / 837
页数：3
相关论文
共 50 条
  • [1] RECOMBINANT HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL-ANTIBODY FAB IS EFFECTIVE THERAPEUTICALLY WHEN INTRODUCED DIRECTLY INTO THE LUNGS OF RSV-INFECTED MICE
    CROWE, JE
    MURPHY, BR
    CHANOCK, RM
    WILLIAMSON, RA
    BARBAS, CF
    BURTON, DR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) : 1386 - 1390
  • [2] Phase III trial of motavizumab, an enhanced potency respiratory syncytial virus (RSV)-specific monoclonal antibody for the prevention of serious RSV disease in high risk infants
    Simoes, E.
    Carbonell, X.
    Losonsky, G.
    Hultquist, M.
    Harris, B.
    Connor, E.
    [J]. ACTA PAEDIATRICA, 2007, 96 : 232 - 233
  • [3] Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
    Malley, R
    DeVincenzo, J
    Ramilo, O
    Dennehy, PH
    Meissner, HC
    Gruber, WC
    Sanchez, PJ
    Jafri, H
    Balsley, J
    Carlin, D
    Buckingham, S
    Vernacchio, L
    Ambrosino, DM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06): : 1555 - 1561
  • [4] Aerosolized respiratory syncytial virus (RSV) antibody treatment of RSV infected cotton rats.
    Devincenzo, JP
    Montana, JB
    Murthy, GGK
    Skornik, WA
    Brain, JD
    Mciver, J
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 101 - 101
  • [5] Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
    Asunción Mejías
    Susana Chávez-Bueno
    Martin B Raynor
    John Connolly
    Peter A Kiener
    Hasan S Jafri
    Octavio Ramilo
    [J]. Virology Journal, 4
  • [6] Motavizumab, a neutralizing anti-respiratory syncytial virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model
    Mejias, Asuncion
    Chavez-Bueno, Susana
    Raynor, Martin B.
    Connolly, John
    Kiener, Peter A.
    Jafri, Hasan S.
    Ramilo, Octavio
    [J]. VIROLOGY JOURNAL, 2007, 4 (1)
  • [7] Viral Concentration in Upper and Lower Respiratory Secretions from Respiratory Syncytial Virus (RSV) Infected Children Treated with RSV Monoclonal Antibody (MEDI-493) † 830
    John P DeVincenzo
    Richard Malley
    Octavio Ramilo
    Penelope H Dennehy
    H Cody Meissner
    William C Gruber
    Pablo J Sanchez
    Hasan Jafri
    James Balsley
    David Carlin
    Steve Buckingham
    Louis Vernacchio
    Donna Ambrosino
    [J]. Pediatric Research, 1998, 43 (Suppl 4) : 144 - 144
  • [8] Palivizumab - the humanised monoclonal antibody for prevention of respiratory syncytial virus (RSV) infection
    Scholz, H
    [J]. ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2000, 204 (03): : 120 - 122
  • [9] Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody
    DeVincenzo, JP
    Aitken, J
    Harrison, U
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (01): : 123 - 126
  • [10] Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease
    Meissner, HC
    Groothuis, JR
    Rodriguez, WJ
    Welliver, RC
    Hogg, G
    Gray, PH
    Loh, R
    Simoes, EAF
    Sly, P
    Miller, AK
    Nichols, AI
    Jorkasky, DK
    Everitt, DE
    Thompson, KA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1183 - 1188
12345